Expertise in
17
conditions

Julia B. Hennermann

Mainz, RP, DE 
Expertise in
17
conditions
Mainz, RP, DE 

Overview

Julia Hennermann practices practicing medicine in Mainz, Germany.

Ms. Hennermann is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Alpha Mannosidosis, Gaucher Disease Type 3, Fabry Disease, and Phenylketonuria (PKU).

She is actively involved in clinical research, co-authoring 100 peer reviewed articles and participating in 9 clinical trials.

Gender

Female

Locations

Mainz, RP, Germany
Other Locations
Gutenberg, RP, Germany
Charité Universitätsmedizin
Berlin, BE, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency
PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency
Enrollment Status: Completed
Publish Date: August 21, 2026
Intervention Type: Drug
Study Drug: PEG-Zilarginase
Study Phase: Phase 3
A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients With MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Years of Age
A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients With MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Years of Age
Enrollment Status: Completed
Publish Date: April 02, 2026
Intervention Type: Drug
Study Drug: Elaprase
Study Phase: Phase 4
Early Detection of Fabry Disease (FD): Using Real-World Data for the Development of Advanced Natural Language Processing Methods: Retrospective Database Analysis
Early Detection of Fabry Disease (FD): Using Real-World Data for the Development of Advanced Natural Language Processing Methods: Retrospective Database Analysis
Enrollment Status: Completed
Publish Date: March 16, 2026
Intervention Type: Other
Natural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) Patients
Natural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) Patients
Enrollment Status: Completed
Publish Date: October 24, 2025
Arimoclomol Prospective Double-blind, Randomised, Placebo-controlled Study in Patients Diagnosed With Niemann-Pick Disease Type C
Arimoclomol Prospective Double-blind, Randomised, Placebo-controlled Study in Patients Diagnosed With Niemann-Pick Disease Type C
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drug: Arimoclomol
Study Phase: Phase 2/Phase 3
A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease
A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease
Enrollment Status: Terminated
Publish Date: June 17, 2024
Intervention Type: Drug
Study Drug: Replagal
Study Phase: Phase 3
MPS VI Clinical Surveillance Program (CSP)
MPS VI Clinical Surveillance Program (CSP)
Enrollment Status: Completed
Publish Date: April 05, 2021
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

100 Total Publications

Prevalence, Disease Onset and Clinical Outcome in Arginase 1 Deficiency: Cross-Border Surveillance in Germany, Austria, and Switzerland.
Prevalence, Disease Onset and Clinical Outcome in Arginase 1 Deficiency: Cross-Border Surveillance in Germany, Austria, and Switzerland.
Journal: Journal of inherited metabolic disease
Published: March 11, 2026

Frequently Asked Questions about Julia B. Hennermann

Is Julia B. Hennermann a top-rated expert for Alpha Mannosidosis?

MediFind is an objective health platform that identifies experts based on real-world data. Julia B. Hennermann is classified as an Elite expert for Alpha Mannosidosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Julia B. Hennermann participate in research or clinical trials?

Yes. Julia B. Hennermann has published 100 articles and abstracts on conditions like Alpha Mannosidosis. You can view a list of Julia B. Hennermann's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hennermann's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
View All 36 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile